The Medicine Cabinet: What’s In It, Why, And Can We Change The Contents?
- 1 January 2004
- journal article
- review article
- Published by Health Affairs (Project Hope) in Health Affairs
- Vol. 23 (1), 23-33
- https://doi.org/10.1377/hlthaff.23.1.23
Abstract
The failure of the pharmaceutical industry to produce drugs for common chronic diseases, emerging diseases, and the potential threats of bioterrorism or the spread of tropical diseases contrasts sharply with the industry’s output of lifestyle and “me-too” drugs. In this paper we review the decision-making process that resulted in our current portfolio of medicines and offer several alternatives to better align business incentives with medical need.Keywords
This publication has 10 references indexed in Scilit:
- The price of innovation: new estimates of drug development costsJournal of Health Economics, 2003
- Returns on Research and Development for 1990s New Drug IntroductionsPharmacoEconomics, 2002
- Perspectives On The Pharmaceutical IndustryHealth Affairs, 2001
- A national study of medical care expenditures for musculoskeletal conditions: The impact of health insurance and managed careArthritis & Rheumatism, 2001
- New drug development in the United States from 1963 to 1999Clinical Pharmacology & Therapeutics, 2001
- The Quality of Care for Depressive and Anxiety Disorders in the United StatesArchives of General Psychiatry, 2001
- Formulating Optimal R&D PortfoliosResearch-Technology Management, 2000
- The Relation between Funding by the National Institutes of Health and the Burden of DiseaseNew England Journal of Medicine, 1999
- Formulary Submission Guidelines for Blue Cross and Blue Shield of Colorado and NevadaPharmacoEconomics, 1999
- DEFINITION AND EPIDEMIOLOGY OF TREATMENT-RESISTANT DEPRESSIONPsychiatric Clinics of North America, 1996